Article Text

Download PDFPDF
Review: allergen specific immunotherapies reduce symptoms, medication requirements, and bronchial hyper-reactivity in asthma

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with asthma, how do different allergen specific (AS) immunotherapies compare for reducing asthma symptoms, medication requirements, and improving bronchial hyper-reactivity (BHR)?

GP/FP/Primary care ★★★★★☆☆ IM/Internal medicine ★★★★★☆☆ Allergy ★★★★★★☆ Respirology ★★★★★☆☆ Immunology ★★★★★★☆


Embedded ImageData sources:

Medline (1966 to December 2001), the Cochrane Airways Group trials register (up to June 2001), EMBASE/Excerpta Medica, CINAHL, Current Contents, abstracts of dissertations, and reference lists.

Embedded ImageStudy selection and assessment:

studies in any language were selected if they were randomised controlled trials (RCTs) comparing AS immunotherapy with placebo, antigenically inactive controls, untreated controls, or inhaled steroids; or comparing house dust extract with placebo. Studies were assessed for methodological quality using the Jadad scale.

Embedded ImageOutcomes:

asthma symptoms, medication requirements, lung …

View Full Text


  • For correspondence: Associate Professor M Abramson, Monash University, Prahran, Victoria, Australia.

  • Source of funding: Garfield Weston Foundation, UK.

  • Abstract and commentary also appear in ACP Journal Club.